TL12-186 NEW
| Price | $66 | $158 | $248 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-15 |
Product Details
| Product Name: TL12-186 | CAS No.: 2250025-88-6 |
| Purity: 98.20% | Supply Ability: 10g |
| Release date: 2026/07/15 |
Product Introduction
Bioactivity
| Name | TL12-186 |
| Description | TL12-186 is a Cereblon-dependent kinase degrader that degrades CDK, BTK, FLT3, Aurora and other kinases.TL12-186 inhibits CDK2/cyclin A and CDK9/cyclin T1 with IC50s of 73 and 55 nM, respectively. |
| In vitro | TL12-186 demonstrates over 90% inhibition against 193 kinases at a screening concentration of 1 μM[1]. Utilizing AlphaScreen binding assays, it exhibits potent binding to CRBN with an IC50 of 12 nM[1]. Displaying CRBN-dependent pharmacological effects, TL12-186 (1-10000 nM; 2 days) exerts 13 to 15 times stronger inhibition of cell survival in WT cells compared to CRBN-/- cells[1]. Moreover, at concentrations ranging from 10 to 10000 nM for 4 hours, TL12-186 selectively inhibits STAT1 phosphorylation without inducing degradation of JAK1/2[1]. |
| Storage | Keep away from direct sunlight,Keep away from moisture, Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (5.37 mM), Sonication is recommended. DMSO : 200 mg/mL (214.72 mM), Sonication is recommended. |
| Keywords | TL12-186 | TL-12186 | TL 12186 | Cereblon | CDK9/cyclin T1 | CDK2/CyclinA |
| Inhibitors Related | Ribociclib | (E)-β-Farnesene | Amantadine | 2-Chloropyrazine | Kojic acid | Abemaciclib | Palbociclib | Abemaciclib methanesulfonate | Sodium Oxamate | Vepdegestrant | 2,4,6-Trihydroxybenzoic acid | Dinaciclib |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Multi-Target Compound Library | Post-Translational Modification Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | High-Efficiency Gene Editing Small Molecule Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
-
CAS:28957-33-7
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1670.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $278.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
|
Hubei Co-Formula Material Tech Co., Ltd.
|
2020-01-17 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY